STAT

AUGUST 15, 2023

4 warning letter , the agency admonished the company for a promotional sales aid that suggested the treatment, called Breztri, had a positive impact on death rates and reduced the risk of death in COPD patients. But the suggestions were not supported by a clinical trial cited in the promotional material, according to the FDA.

FDA 98

FDA 98

Hospital Pharmacy Europe

SEPTEMBER 14, 2023

Using lung progenitor cell transplantation in patients with chronic obstructive pulmonary disease (COPD) appears to improve symptoms and could lead to a cure, according to a study presented at the recent European Respiratory Society (ERS) International Congress 2023 in Milan, Italy. However, we cannot repair severe emphysema yet.‘

Hospitals 52

Hospitals 52

PQA

SEPTEMBER 26, 2022

PQA has appointed 15 individuals from member organizations to serve on a technical expert panel (TEP) to review and provide input on draft specification for a health plan performance measure concept: COPD (chronic obstructive pulmonary disease) Treatment Ratio (CTR). like COPD Treatment Ratio (CTR) TEP.? during the treatment period.?

76

76

European Pharmaceutical Review

NOVEMBER 21, 2023

If successful this could lead to regulatory submissions in 2025, supporting the health of asthma and COPD patients and making a significant positive impact on our transition to a more environmentally sustainable future,” GSK’s Chief Executive Officer, Emma Walmsley commented.

112

112

Pharmacy Is Right For Me

FEBRUARY 22, 2024

Joining the Family Medicine Clinic during his residency provided Mohanad with exposure to ambulatory care, where he found his impact and strong fit immediately. These encounters can take place in the clinic, via telephone, or through Telemedicine.

Community Pharmacies 130

Community Pharmacies Scheduling Appointments Hospitals 130

Hospital Pharmacy Europe

NOVEMBER 14, 2022

Similarly, given that dipeptidyl peptidase 4 expression is increased in the lungs of those with COPD, leading to inflammation, the DPP-4 inhibitors have a possible role in the disease through a reduction in lung inflammation. Oral anti-diabetic drugs and COPD exacerbations.

Hospitals 52

Hospitals 52

pharmaphorum

NOVEMBER 19, 2021

More than 100 million Americans affected by COPD, COVID-19 and asthma. “There is a clear difference in the acoustic resonance spectra of COPD patients versus healthy controls,” she added. “She suffered from COPD and had a sudden exacerbation of her symptoms and tragically died.

Hospitals 121

Hospitals FDA 121

pharmaphorum

MARCH 11, 2021

Unlocking the clinical value of the EHR with AI and Big Data whist ensuring the safety of patient data at all times. Dr Ignacio H Medrano, CMO and founder, Savana is a consultant neurologist with training in healthcare management and experience in clinical research strategies – formerly responsible for +500 researchers.

109

109

Hospital Pharmacy Europe

SEPTEMBER 11, 2023

Guidance on how global warming can be addressed in clinical practice has been outlined by the European Respiratory Society (ERS) in its latest consensus statement on climate change and respiratory health. We also need to explain the risks to our patients so they can protect themselves from adverse effects of climate change.‘

Hospitals 105

Hospitals 105

Med Ed 101

APRIL 3, 2022

Asthma and COPD are two disease states that we need to use inhalers. As a clinical pharmacist, I understand the importance of patient education. I’ve seen numerous mistakes with inhaler technique over the years in my practice as a clinical pharmacist. Here are some of those examples.

45

45

Pharmafile

APRIL 11, 2023

Published date: 11/04/2023 Summary: LONDON and RALEIGH, N.C., LONDON and RALEIGH, N.C., read more LONDON and RALEIGH, N.C., read more

40

40

Med Ed 101

MARCH 27, 2022

COPD is a challenging disease that ultimately leads to a progressive reduction in lung function. Roflumilast (podcast) is a unique medication for COPD in that it is taken orally. I want to discuss roflumilast clinical pearls and where this medication might be […].

40

40

pharmaphorum

AUGUST 14, 2020

Based in the UK and US, Verona is due to start a phase 3 trial of ensifentrine in chronic obstructive pulmonary disease (COPD) later this year after encouraging results in phase 2. Zaccardelli took over as CEO in February, replacing Jan-Anders Karlsson, who retired after eight years to pursue non-executive roles.

Compounding 110

Compounding FDA 110

pharmaphorum

NOVEMBER 14, 2022

Sanofi and Regeneron are running a phase 3 trial of the drug in COPD patients with type 2 inflammation called NOTUS that is due to generate results next year. Sanofi and Regeneron have predicted that Dupixent could make around $13 billion a year at peak, which would propel the drug into the top five biggest pharmaceutical sellers.

Immunization 117

Immunization FDA 117

PQA

AUGUST 25, 2022

PQA, the Pharmacy Quality Alliance, has begun developing a health plan performance measure for chronic obstructive pulmonary disease (COPD). Chronic lower respiratory disease, primarily COPD, is the fourth leading cause of death in the United States. million Americans have been diagnosed with COPD.

40

40

Pharmaceutical Technology

NOVEMBER 28, 2022

Under the agreement, AstraZeneca will be responsible for the development and marketing of oral therapy for inflammatory and respiratory diseases with a key focus on chronic obstructive pulmonary disease (COPD). This includes an upfront payment of $2m from AstraZeneca. Additionally, AstraZeneca will make a potential payment of $385.8m

Immunization 105

Immunization 105

Hospital Pharmacy Europe

APRIL 10, 2024

One area of practice in which clinical pharmacists are particularly impactful is respiratory medicine. In December 2023, the European Respiratory Society journal, Breathe , published a paper extolling the many and varied ways in which clinical pharmacists add knowledge and value in respiratory and sleep medicine.

Hospitals 52

Hospitals Patient Care 52

Hospital Pharmacy Europe

NOVEMBER 23, 2023

‘If successful this could lead to regulatory submissions in 2025, supporting the health of asthma and COPD patients and making a significant positive impact on our transition to a more environmentally sustainable future.’

Hospitals 52

Hospitals 52

Pharmaceutical Technology

SEPTEMBER 5, 2022

An example of AstraZeneca’s deals in the cardiovascular disease clinical landscape is its agreement with US-based Dogma Therapeutics. In 2021, AstraZeneca sold $270 million worth of assets to Covis Pharma, which then transferred AstraZeneca’s chronic obstructive pulmonary disease (COPD) inhalers Tudorza and Duaklir to Covis.

FDA 114

FDA Vaccines 114

pharmaphorum

DECEMBER 19, 2022

It would provide an alternative to standard breathing exercises for patients with conditions that affect breathing, including long-term respiratory diseases like asthma, chronic obstructive pulmonary disorder (COPD) and cystic fibrosis, which can be resource-intensive as they require patients to be overseen by a healthcare worker.

145

145

pharmaphorum

FEBRUARY 2, 2021

UK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after a formulation delivered with an inhaler met its goals in a phase 2 trial. The post Boost for Verona Pharma after trial win with inhaled COPD drug appeared first on.

Compounding 40

Compounding 40

PharmaShots

JUNE 13, 2023

AstraZeneca announces Results of AERISTO P-IIIb trial for Bevespi Aerosphere in COPD patients Published: 23Aug,2018 | Tags: AstraZeneca, Announces, AERISTO P-IIIb, Bevespi Aerosphere, COPD 4. AbbVie Exercises Exclusive Option to License Argenx's ARGX-115 Published: 22 Aug,2018 | Tags: AbbVie, Argenx, Option to License, ARGX-115 8.

Labelling 52

Labelling FDA 52

Hospital Pharmacy Europe

MAY 22, 2023

In support of our mission to provide high-quality clinical education, Hospital Pharmacy Europe is proud to announce the second in its new series of Clinical Excellence events in partnership with Hospital Healthcare Europe. Save the date! And register to join us on 12 July 2023!

Hospitals 52

Hospitals Patient Care 52

pharmaphorum

OCTOBER 26, 2022

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis and other interstitial lung diseases (ILDs). ” The post Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3 appeared first on.

Labelling 98

Labelling FDA 98

pharmaphorum

JANUARY 17, 2023

Unify, launched in December 2020, is AstraZeneca’s patient app and clinical trial support tool. Attrition in drug development for chronic disease is high, often because the wrong patients are selected for clinical trials,” Challis explained. Digital technology and ‘frictionless’ clinical trials. Dissecting heterogeneity.

98

98

The Checkup by Singlecare

JANUARY 18, 2024

Key takeaways | Drug interactions | Food interactions | Other interactions | Avoiding interactions | When to see a doctor Albuterol (Ventolin HFA) is a quick-relief medication used to treat bronchospasm in people with asthma or chronic obstructive pulmonary disease (COPD). It is also effective in treating exercise-induced bronchospasm.

Dosage 52

Dosage 52

pharmaphorum

FEBRUARY 11, 2021

The generic respiratory drug budesonide could be an option to treat COVID-19, a small scale clinical study has suggested. Researchers decided to begin the trial after noticing that people with asthma or chronic obstructive pulmonary disease (COPD) were surprisingly underrepresented among patients hospitalised with COVID-19.

98

98

Med Ed 101

DECEMBER 11, 2019

These agents have been commonly used in the setting of asthma and COPD. The post The Clinical Difference Between Salmeterol and Formoterol appeared first on Med Ed 101. Each of these agents is most commonly combined with an inhaled corticosteroid. Budesonide is coupled with formoterol in the brand name product Symbicort.

40

40

pharmaphorum

APRIL 14, 2022

ResApp’s technology was created to detect a wide range of respiratory conditions such as pneumonia, asthma, bronchiolitis and chronic obstructive pulmonary disease (COPD) using only the sound of a patient’s cough.

74

74

pharmaphorum

JUNE 17, 2022

It’s also possible that the big pharma is interested in Mereo ‘s other clinical-stage candidates, such as its anti-TIGIT antibody etigilimab which is being tested for cancer alongside PD-1/PD-L1 inhibitors.

81

81

Pharmaceutical Technology

APRIL 26, 2023

Dr. Amy Chan, senior clinical research fellow at the School of Pharmacy, University of Auckland, says digital inhalers have existed for almost 30 years. In a 2020 study, Chan found devices that can easily calculate adherence to activation and inhalation could have the greatest utility in clinical practice.

Medication Delivery 115

Medication Delivery Communication 115

The Checkup by Singlecare

NOVEMBER 13, 2023

Causes of sharp right-side chest pain Sharp pain on the right side of the chest is a common clinical symptom, and it can be due to a variety of causes that may be related to the lungs, chest muscles, digestive system, or an infection. According to the Centers for Disease Control and Prevention (CDC) , about 16 million Americans have COPD.

Mayo Clinic 52

Mayo Clinic Vaccines Chemotherapy Communication 52

pharmaphorum

MARCH 27, 2022

The two companies say they plan to launch a series of Software as a Medical Device (SaMD) companion apps for various diseases, including asthma, chronic obstructive pulmonary disease (COPD) and heart failure, as well as technology for running decentralised clinical trials.

Hospitals 58

Hospitals 58

pharmaphorum

JANUARY 18, 2022

As it is easy to use – sprayed up the nostrils – it has the potential to be a game-changing prophylactic for people at increased risk of illness – such as older people, those with COPD, and asthmatics. We look forward to updating the market as POLB 002 progresses through the clinic with the ultimate aim of partnering it with Big Pharma.”.

Vaccines 58

Vaccines 58

pharmaphorum

JULY 28, 2022

The drug is also being tested in some forms of chronic obstructive pulmonary disease (COPD), and various conditions leading to urticaria (hives), although it fell short in a phase 3 trial in chronic spontaneous urticaria (CSU) earlier this year. The post Dupixent drives Sanofi to hike its full-year profit forecasts appeared first on.

Vaccines 58

Vaccines FDA 58

pharmaphorum

DECEMBER 14, 2021

It said the company expects to employ 155 clinicians by the middle of next year, who will provide remote care to people with chronic conditions such as hypertension, chronic obstructive pulmonary disease (COPD) and type 2 diabetes. It promises to deliver improved clinical outcomes and a “world-class” patient experience.

Hospitals 52

Hospitals 52

pharmaphorum

OCTOBER 4, 2021

The 14 winners are: Guy’s and St Thomas’ NHS Foundation Trust and Royal Devon and Exeter NHS Trust, for a respiratory remote monitoring programme, partnered with patientMpower ; One Health Lewisham for a clinical messaging for hypertension support platform partnered with Doctaly Assist ; Guy’s and St Thomas’ NHS Foundation (..)

Hospitals 113

Hospitals 113